Medical

The International Primary Care Respiratory Group (IPCRG) has launched a petition in support of its Fresh Air Uganda study in response to what it says is a growing threat in the region, with COPD expected to surpass HIV/AIDs as the third-leading cause of death in Africa by 2025. The epidemiological study in rural Uganda will involve 600 people over the age of 30, … [Read more...] about Effort to study COPD prevalence in Sub-Saharan African launched

Massachusetts biotech company Pulmatrix presented data from two studies of its Pulmatrix presents data from preclinical studies of its lead product, PUR118, an inhaled cationic airway lining modulator (iCALM) for the treatment of respiratory diseases in oral and poster sessions at the 2011 European Respiratory Society (ERS) conference. The data show that PUR118 … [Read more...] about Pulmatrix presents data from preclinical studies of its inhaled calcium salts

Almirall has presented a number of posters at the 2011 Annual Congress of the European Respiratory Society (ERS), including, for the first time, full data from the six-month Phase 3 ATTAIN study of its aclidinium bromide dry powder inhaler for the treatment of moderate-to-severe COPD. The data show that twice-daily doses of either 200 μg or 400 μg of aclidinium … [Read more...] about Amirall presents full data for Phase 3 ATTAIN study of aclidinium bromide at ERS

MicroDose Therapeutx has initiated a Phase 1 clinical trial of MDT-637, an inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV) that is delivered using the company's novel dry powder nebulizer. MicroDose is developing MDT-637 in partnership with Gilead Sciences and will develop the product through Phase 2a trials. … [Read more...] about MicroDose begins Phase 1 trial of novel dry powder nebulized treatment for RSV

Two posters presented by Pearl Therapeutics at the 2011 European Respiratory Society meeting show additional data from a Phase 2b study demonstrating that Pearl's glycopyrrolate (GP)/fomoterol fumarate (FF) fixed combination metered dose inhaler and its PT001 GP monotherapy MDI both provide greater inspiratory capacity than Spiriva Handihaler tiotropium dry powder … [Read more...] about Pearl Therapeutics announces positive Phase 2b results for PT003 inhaler

According to Mundipharma, three Phase 3 studies of the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) have demonstrated that the product "had comparable efficacy in improving the lung function and a similar safety profile to budesonide/formoterol, a licensed combination asthma therapy," "was as effective in treating asthma as … [Read more...] about Phase 3 studies presented at ERS show efficacy and safety of Flutiform

Elevation Pharmaceuticals has presented positive results from a Phase 2a study of its glycopyrrolate inhalation solution in patients with moderate to severe COPD at the European Respiratory Society (ERS) meeting in Amsterdam. If Elevation can bring the formulation, known as EP-101, to market, it would be the first long-acting muscarinic antagonist (LAMA) available for … [Read more...] about Positive Phase 2a results for Elevation’s glycopyrrolate inhalation solution

The European Lung Foundation has launched a website for its AirPROM consortium, a group formed "to integrate and enhance the capacities of all partners to deliver the best possible outcome for people with asthma and chronic obstructive pulmonary disease (COPD)." The AirPROM name stands for "Airway Disease Predicting Outcomes through Patient Specific Computational … [Read more...] about Website for AirPROM consortium launched

The Congress of Delegates of the American Academy of Family Physicians (AAFP) has approved a resolution calling for the organization "to work with public and private payers to ensure the lowest copays for at least one inhaled steroid and one short-acting, beta adrenergic inhaler in their drug formularies with any copays at the lowest tier level, and one … [Read more...] about American Academy of Family Physicians calls for affordable inhalers